BiotechTube

Ciclesonide

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bronchial Asthma

Conditions

Bronchial Asthma

Trial Timeline

Nov 1, 2011 → Aug 1, 2014

NCT ID
NCT01455194

About Ciclesonide

Ciclesonide is a phase 3 stage product being developed by AstraZeneca for Bronchial Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01455194. Target conditions include Bronchial Asthma.

What happened to similar drugs?

3 of 15 similar drugs in Bronchial Asthma were approved

Approved (3) Terminated (3) Active (9)
🔄Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
🔄90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
🔄Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUATCiplaPhase 3
🔄Test Product + Reference Product + PlaceboAurobindo PharmaPhase 3
❌Albuterol Sulfate HFA 0.09 mg (Reference) + Albuterol Sulfate HFA 0.18 mg (Reference) + Albuterol Sulfate HFA 0.09 mg (Test) + Albuterol Sulfate HFA 0.18 mg (Test) + PlaceboAurobindo PharmaPhase 3
🔄Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhalerGlenmark PharmaceuticalsPhase 3
🔄Symbicort Turbuhaler + Symbicort pMDI + Pulmicort TurbuhalerAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (19)

NCT IDPhaseStatus
NCT01455194Phase 3Completed
NCT00608218Pre-clinicalCompleted
NCT00305461Phase 3Completed
NCT00261287Phase 3Completed
NCT00163371Phase 3Completed
NCT00163436Phase 3Completed
NCT00163488Phase 3Completed
NCT00163423Phase 3Completed
NCT00163319Phase 3Completed
NCT00163462Phase 3Completed
NCT00163514Phase 3Completed
NCT00163384Phase 3Completed
NCT00163397Phase 3Completed
NCT00163501Phase 3Completed
NCT00163345Phase 3Completed
NCT00163358Phase 3Completed
NCT00163410Phase 3Completed
NCT00163332Phase 3Completed
NCT00546520Phase 3Completed

Competing Products

20 competing products in Bronchial Asthma

See all competitors
ProductCompanyStageHype Score
TacrolimusAstellas PharmaPhase 2
35
tacrolimusAstellas PharmaPhase 2
35
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
40
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
40
Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUATCiplaPhase 3
40
Test Product + Reference Product + PlaceboAurobindo PharmaPhase 3
40
Albuterol Sulfate HFA 0.09 mg (Reference) + Albuterol Sulfate HFA 0.18 mg (Reference) + Albuterol Sulfate HFA 0.09 mg (Test) + Albuterol Sulfate HFA 0.18 mg (Test) + PlaceboAurobindo PharmaPhase 3
32
Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhalerGlenmark PharmaceuticalsPhase 3
36
Symbicort Turbuhaler + Symbicort pMDI + Pulmicort TurbuhalerAstraZenecaPhase 3
40
RoflumilastAstraZenecaPhase 3
40
RoflumilastAstraZenecaPhase 2/3
38
Symbicort (budesonide/formoterol) Turbuhaler + Conventional treatmentAstraZenecaPhase 3
32
Montelukast plus prednisolone + PrednisoloneMerckPhase 2
35
MontelukastMerckApproved
43
Formoterol fumerate + fenoterol/ipratropium bromideNovartisApproved
43
inhaled corticosteroid therapyNovartisPhase 1/2
32
PF-00610355 + PF - 00610355 + PF - 00610355PfizerPhase 2
27
NivolumabBristol Myers SquibbPhase 2
39
HSK31858 + PlaceboHaisco Pharmaceutical GroupPhase 2
42
HSK31858 + PlaceboHaisco Pharmaceutical GroupPhase 2
42